1. Home
  2. BB vs AGIO Comparison

BB vs AGIO Comparison

Compare BB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackBerry Limited

BB

BlackBerry Limited

HOLD

Current Price

$3.56

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$34.88

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BB
AGIO
Founded
1984
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
BB
AGIO
Price
$3.56
$34.88
Analyst Decision
Hold
Buy
Analyst Count
4
8
Target Price
$4.90
$38.50
AVG Volume (30 Days)
7.9M
851.4K
Earning Date
04-09-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
40.91
N/A
EPS
0.05
N/A
Revenue
$534,900,000.00
$43,011,000.00
Revenue This Year
$4.19
$74.95
Revenue Next Year
$7.63
$165.77
P/E Ratio
$69.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.81
$22.24
52 Week High
$5.32
$46.00

Technical Indicators

Market Signals
Indicator
BB
AGIO
Relative Strength Index (RSI) 60.82 75.41
Support Level $3.55 $26.64
Resistance Level $3.59 $43.72
Average True Range (ATR) 0.12 1.36
MACD 0.04 0.74
Stochastic Oscillator 93.62 82.57

Price Performance

Historical Comparison
BB
AGIO

About BB BlackBerry Limited

BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: